#78
Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Clinicians treating temporomandibular disorder patients now have emerging evidence supporting cannabis extracts as a potential therapeutic option for myofascial pain management. This trial-derived data enables informed discussions with patients about an alternative or adjunctive treatment that may reduce reliance on opioids or other conventional analgesics. The sublingual delivery method demonstrated in this trial offers practical dosing information for clinicians considering cannabis-based interventions in their pain management protocols.
A clinical trial examining sublingual cannabis extract administration demonstrated significant pain reduction in patients with temporomandibular disorder (TMD) and associated myofascial pain, supporting the potential therapeutic utility of this delivery route for localized musculoskeletal conditions. The sublingual route offers particular advantages for orofacial pain management given direct mucosal absorption and rapid onset of action, which may benefit patients who experience inadequate pain control with conventional analgesics or physical therapy alone. These findings add to the growing evidence base for cannabis-derived therapeutics in pain management, though clinicians should note that TMD treatment typically involves a multimodal approach including physical therapy, occlusal adjustment, and behavioral modification. The sublingual delivery method warrants further investigation in larger, longer-duration trials to establish optimal dosing, safety profiles with concurrent medications, and comparative efficacy against standard TMD pain management protocols. Clinicians considering cannabis extracts for myofascial pain should counsel patients on the evidence base specific to their condition, potential drug interactions, and the importance of integrating cannabis use with other evidence-based TMD treatments rather than substituting them. For patients with refractory myofascial pain unresponsive to conventional therapies, sublingual cannabis extract may represent an additional therapeutic option worth discussing, though it should be prescribed within a comprehensive pain management plan.
“What this trial demonstrates is that we finally have rigorous evidence for something patients have been telling us for years: cannabis works for myofascial pain conditions like TMD, and the sublingual route gives us predictable dosing and faster onset than smoking. I’m now comfortable discussing this with appropriate patients as a legitimate option when conventional treatments haven’t worked, rather than defaulting to opioids or ineffective muscle relaxants.”
💊 While this trial showing cannabis extract efficacy for temporomandibular disorder-related myofascial pain is encouraging, clinicians should recognize that a single positive trial, particularly from a source with advocacy interests, requires replication and independent verification before confidently recommending cannabis for this indication. The trial’s design details, blinding procedures, control group characteristics, and long-term safety data remain important unknowns that limit immediate clinical translation, and individual patient factors such as substance use history, drug interactions with current medications, and local regulatory status must be carefully evaluated. Additionally, myofascial pain conditions often respond to multimodal approaches including physical therapy, behavioral interventions, and conventional analgesics, making it difficult to isolate cannabis’s unique contribution in typical clinical practice. For now, clinicians encountering patients with refractory temporomandibular myofascial pain who express interest in cannabis might cautiously discuss this emerging evidence while emphasizing
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it: